Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines
Context We present an overview of the updated 2023 European Association of Urology
(EAU) guidelines for muscle-invasive and metastatic bladder cancer (MMIBC). Objective To …
(EAU) guidelines for muscle-invasive and metastatic bladder cancer (MMIBC). Objective To …
European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines
Context This overview presents the updated European Association of Urology (EAU)
guidelines for muscle-invasive and metastatic bladder cancer (MMIBC). Objective To …
guidelines for muscle-invasive and metastatic bladder cancer (MMIBC). Objective To …
Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer
Rationale: Siglec15 is an emerging target for normalization cancer immunotherapy.
However, pan-cancer anti-Siglec15 treatment is not yet validated and the potential role of …
However, pan-cancer anti-Siglec15 treatment is not yet validated and the potential role of …
[HTML][HTML] Different responses to neoadjuvant chemotherapy in urothelial carcinoma molecular subtypes
Background For muscle-invasive bladder cancer (MIBC), no tissue biomarkers are available
for clinical use to predict response to neoadjuvant chemotherapy. Objective To investigate …
for clinical use to predict response to neoadjuvant chemotherapy. Objective To investigate …
BCAT2 Shapes a Noninflamed Tumor Microenvironment and Induces Resistance to Anti‐PD‐1/PD‐L1 Immunotherapy by Negatively Regulating Proinflammatory …
Z Cai, J Chen, Z Yu, H Li, Z Liu, D Deng, J Liu… - Advanced …, 2023 - Wiley Online Library
To improve response rate of monotherapy of immune checkpoint blockade (ICB), it is
necessary to find an emerging target in combination therapy. Through analyzing tumor …
necessary to find an emerging target in combination therapy. Through analyzing tumor …
Non–muscle-invasive bladder cancer molecular subtypes predict differential response to intravesical Bacillus Calmette-Guérin
The recommended treatment for patients with high-risk non–muscle-invasive bladder cancer
(HR-NMIBC) is tumor resection followed by adjuvant Bacillus Calmette-Guérin (BCG) …
(HR-NMIBC) is tumor resection followed by adjuvant Bacillus Calmette-Guérin (BCG) …
BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer
M Rouanne, J Adam, C Radulescu, D Letourneur… - The Journal of clinical …, 2022 - jci.org
Patients with high-risk, nonmuscle-invasive bladder cancer (NMIBC) frequently relapse after
standard intravesical bacillus Calmette-Guérin (BCG) therapy and may have a dismal …
standard intravesical bacillus Calmette-Guérin (BCG) therapy and may have a dismal …
Robotic urologic surgical interventions performed with the single port dedicated platform: first clinical investigation
J Kaouk, J Garisto, R Bertolo - European Urology, 2019 - Elsevier
We report the first clinical investigation for surgical procedures performed using the da Vinci
SP robotic surgical platform (Intuitive Surgical, Sunnyvale, CA, USA) during the first 10 days …
SP robotic surgical platform (Intuitive Surgical, Sunnyvale, CA, USA) during the first 10 days …
[HTML][HTML] Novel therapeutic opportunities in neoadjuvant setting in urothelial cancers: a new horizon opened by molecular classification and immune checkpoint …
ML Iacovino, CC Miceli, M De Felice, B Barone… - International journal of …, 2022 - mdpi.com
Muscle invasive bladder cancer (MIBC) is a widespread malignancy with a worse prognosis
often related to a late diagnosis. For early-stage MIBC pts, a multidisciplinary approach is …
often related to a late diagnosis. For early-stage MIBC pts, a multidisciplinary approach is …
Immunotherapy in urothelial cancer: current status and future directions
C Piombino, E Tonni, M Oltrecolli, M Pirola… - Expert Review of …, 2023 - Taylor & Francis
Introduction Since 2016, the progressive use of immune checkpoint inhibitors (ICIs) starting
from second-line treatment has led to an improvement in overall survival in locally advanced …
from second-line treatment has led to an improvement in overall survival in locally advanced …